Early Anti-inflammatory and Pro-angiogenic Myocardial Effects of Intravenous Serelaxin Infusion for 72 H in an Experimental Rat Model of Acute Myocardial Infarction
- 17 July 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Cardiovascular Translational Research
- Vol. 10 (5-6), 460-469
- https://doi.org/10.1007/s12265-017-9761-1
Abstract
Sprague Dawley rats were subjected to acute myocardial infarction (AMI) by permanent ligation of the left anterior descending coronary artery. At the time of AMI, a subcutaneous mini-osmotic pump was implanted and animals were randomized into three groups, according to the intravenous therapy received during the first 72 h: placebo-treated (saline), serelaxin10-treated (SRLX10 = 10 μg/kg/day), or serelaxin30-treated (SRLX30 = 30 μg/kg/day). Treatment with SRLX30 reduced the expression of inflammatory cytokines and chemokines, as well as the infiltration of macrophages, and increased the expression of pro-angiogenic markers and vessel density in the infarcted myocardium after 7 days. SRLX30 did not reduce early myocardial fibrosis but reduced myocardial levels of sST2 and galectin-3. No significant effects were observed with SRLX10 treatment. A significant correlation was observed between plasma levels of serelaxin and effect measures. The results suggest serelaxin has a protective effect in early processes of cardiac remodeling after AMI.Keywords
Funding Information
- Instituto de Salud Carlos III (PI14/01637, INT16/00172, CD13/00032)
- Novartis Pharma
This publication has 24 references indexed in Scilit:
- Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 studyEuropean Journal of Heart Failure, 2017
- Fibroblasts in post-infarction inflammation and cardiac repairBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2013
- Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trialThe Lancet, 2012
- Identification of Key Residues Essential for the Structural Fold and Receptor Selectivity within the A-chain of Human Gene-2 (H2) RelaxinPublished by Elsevier BV ,2012
- Cellular retrograde cardiomyoplasty and relaxin therapy for postischemic myocardial repair in a rat model.2012
- Relaxin remodels fibrotic healing following myocardial infarctionLaboratory Investigation, 2011
- Relaxin is a candidate drug for lung preservation: Relaxin-induced protection of rat lungs from ischemia-reperfusion injuryThe Journal of Heart and Lung Transplantation, 2010
- Relaxin Reverses Cardiac and Renal Fibrosis in Spontaneously Hypertensive RatsHypertension, 2005
- Relaxin protects against myocardial injury caused by ischemia and reperfusion in rat heart.1998
- Relaxin Counteracts Myocardial Damage Induced by Ischemia-Reperfusion in Isolated Guinea Pig Hearts: Evidence for an Involvement of Nitric Oxide*Endocrinology, 1997